These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 2073585)
1. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Schneider JS Brain Res; 1990 Nov; 534(1-2):25-36. PubMed ID: 2073585 [TBL] [Abstract][Full Text] [Related]
2. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Pifl C; Hornykiewicz O Neurochem Int; 2006 Oct; 49(5):519-24. PubMed ID: 16698121 [TBL] [Abstract][Full Text] [Related]
3. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Irwin I; DeLanney LE; Forno LS; Finnegan KT; Di Monte DA; Langston JW Brain Res; 1990 Oct; 531(1-2):242-52. PubMed ID: 1981162 [TBL] [Abstract][Full Text] [Related]
4. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Rioux L; Frohna PA; Joyce JN; Schneider JS Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972 [TBL] [Abstract][Full Text] [Related]
5. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial. Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239 [TBL] [Abstract][Full Text] [Related]
6. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Schneider JS; Kovelowski CJ Brain Res; 1990 Jun; 519(1-2):122-8. PubMed ID: 2397401 [TBL] [Abstract][Full Text] [Related]
7. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. Ouattara B; Gasparini F; Morissette M; Grégoire L; Samadi P; Gomez-Mancilla B; Di Paolo T J Neurochem; 2010 May; 113(3):715-24. PubMed ID: 20132464 [TBL] [Abstract][Full Text] [Related]
8. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sirinathsinghji DJ; Whittington PE; Audsley AR Brain Res; 1986 Dec; 399(2):339-45. PubMed ID: 2435361 [TBL] [Abstract][Full Text] [Related]
9. Increased DAT binding in the early stage of the dopaminergic lesion: a longitudinal [11C]PE2I binding study in the MPTP-monkey. Vezoli J; Dzahini K; Costes N; Wilson CR; Fifel K; Cooper HM; Kennedy H; Procyk E Neuroimage; 2014 Nov; 102 Pt 2():249-61. PubMed ID: 25108180 [TBL] [Abstract][Full Text] [Related]
10. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys. Di Paolo T; Bédard P; Daigle M; Boucher R Brain Res; 1986 Aug; 379(2):286-93. PubMed ID: 2427166 [TBL] [Abstract][Full Text] [Related]
11. Aged monkeys as a partial model for Parkinson's disease. Hurley PJ; Elsworth JD; Whittaker MC; Roth RH; Redmond DE Pharmacol Biochem Behav; 2011 Sep; 99(3):324-32. PubMed ID: 21620883 [TBL] [Abstract][Full Text] [Related]
12. Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Cenci MA; Kalén P; Mandel RJ; Björklund A Brain Res; 1992 May; 581(2):217-28. PubMed ID: 1393530 [TBL] [Abstract][Full Text] [Related]
13. Cognitive changes in mice following moderate MPTP exposure. Tanila H; Björklund M; Riekkinen P Brain Res Bull; 1998 Apr; 45(6):577-82. PubMed ID: 9566501 [TBL] [Abstract][Full Text] [Related]
14. Dopamine and homovanillic acid concentrations in striatal and limbic regions of human brain. Walsh FX; Stevens TJ; Langlais PJ; Bird ED Ann Neurol; 1982 Jul; 12(1):52-5. PubMed ID: 7114818 [TBL] [Abstract][Full Text] [Related]
15. Short-term atrazine exposure causes behavioral deficits and disrupts monoaminergic systems in male C57BL/6 mice. Lin Z; Dodd CA; Filipov NM Neurotoxicol Teratol; 2013; 39():26-35. PubMed ID: 23770127 [TBL] [Abstract][Full Text] [Related]
16. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626 [TBL] [Abstract][Full Text] [Related]
17. Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Barbiero JK; Santiago RM; Lima MM; Ariza D; Morais LH; Andreatini R; Vital MA Behav Brain Res; 2011 Jan; 216(1):186-92. PubMed ID: 20688106 [TBL] [Abstract][Full Text] [Related]
18. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947 [TBL] [Abstract][Full Text] [Related]
19. A potential compensatory role for endogenous striatal tyrosine hydroxylase-positive neurons in a nonhuman primate model of Parkinson's disease. Bubak AN; Redmond DE; Elsworth JD; Roth RH; Collier TJ; Bjugstad KB; Blanchard BC; Sladek JR Cell Transplant; 2015; 24(4):673-80. PubMed ID: 25839107 [TBL] [Abstract][Full Text] [Related]
20. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys. Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]